Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
Cancers (Basel)
; 13(8)2021 Apr 13.
Article
in En
| MEDLINE
| ID: mdl-33924378
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Risk_factors_studies
Language:
En
Journal:
Cancers (Basel)
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: